查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848552

灰指甲治疗市场按药物类型、活性成分、剂型、分销管道、治疗场所、年龄层、性别和疾病严重程度划分－2025-2032年全球预测

Onychomycosis Treatment Market by Drug Type, Active Ingredient, Formulation, Distribution Channel, Treatment Setting, Age Group, Gender, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，灰指甲治疗市场规模将成长 43 亿美元，复合年增长率为 9.40%。

主要市场统计数据
基准年 2024 20.9亿美元
预计年份：2025年 22.9亿美元
预测年份：2032年 43亿美元
复合年增长率 (%) 9.40%

阐述甲癣的当代临床和商业性格局，重点关注未满足的需求、相关人员的动态以及不断发展的治疗途径

由于人口老化、併发症增加以及患者对治疗耐受性和便利性的期望不断提高，灰指甲在临床和商业性持续面临挑战。临床医师因甲癣的非典型表现和混合病因而面临诊断难题，而患者往往因顾虑外观或认为既往治疗无效而延误就医，造成巨大的未满足医疗需求。

近年来，治疗方法的进步，包括更具标靶性的局部抗真菌药物、口服药物的创新以及雷射疗法等辅助技术，正在丰富治疗途径，并为不同患者群体提供更多选择。然而，在依从性、长期復发预防和真实世界疗效方面，仍有数据空白。支付者和医疗服务提供者正逐渐采用以价值主导的决策标准，强调安全性、治疗持续时间和病患报告结局的显着改善。

此次聘用整合了临床背景、相关人员和不断变化的治疗动态，同时为深入探索影响甲癣治疗产品开发、开发策略和竞争定位的监管、经济和竞争力量奠定了基础。

治疗创新、製剂改良和渐进式治疗给药方式如何重新定义足癣的治疗选择、依从性和商业化

随着治疗方法创新与患者期望和治疗模式的转变，甲癣的治疗格局正在变革时期。治疗方法正从单一药物联合治疗转向综合治疗方案，将外用药物、口服药物、器械辅助治疗和支持性措施相结合，以提高疗效和患者依从性。这种多维度的策略正在重新思考临床医生如何选择轻度和重度甲癣的治疗方法，以及製造商如何在临床讯息中突出产品优势。

同时，对製剂科学的投入正在提升渗透促进剂、新型载体系统和易用性方面的作用，从而解决长期存在的障碍，例如指甲渗透缓慢和治疗週期过长。新的活性成分和製剂策略正在接受测试，旨在降低復发率并提高疗效持久性，而安全性和药物交互作用仍然是多重用药族群（尤其是老年人）采用这些药物的关键因素。

在医疗服务提供方面，数位化管道和远端医疗服务正在重塑患者就医和追踪方式，从而实现早期疗育和更有效的依从性监测。药房模式也在适应这一转变，除了传统的医院和零售管道外，线上药局和居家照护管道也日益普及。这些变革性趋势既为创造差异化的临床价值带来了机会，也为市场准入带来了挑战，因此需要製定一个综合性的商业化计划，该计划需兼顾监管细则、支付方期望以及以患者为中心的定位。

评估美国关税对供应链、采购和采购的影响（截至2025年）

美国在2025年前实施的新关税政策，正对皮肤科和抗真菌产品的供应链、筹资策略和定价动态产生连锁反应。从国际市场购买活性原料药、辅料和最终产品的製造商正在调整其采购布局和合约条款，以降低进口关税和海关相关时间风险。此类调整通常会导致供应计划的改变，进而影响分销点的产品供应和库存缓衝。

短期应对措施包括将零件采购转移到国内或低关税地区，重新谈判供应商合约以纳入关税分摊条款，以及有选择地增加关键SKU的国内库存。长期来看，企业正在评估近岸製造和本地化配方设施，以此作为应对关税带来的成本压力的结构性措施。这些策略性投资可以降低贸易波动带来的风险，但需要做出影响产品上市时间和利润率结构的资本配置决策。

支付者和采购团队也积极应对，收紧合约条款，强调基于价值的合作模式，并仔细审查医疗总成本。临床负责人和采购部门可能倾向于选择那些在安全性或依从性方面具有差异化优势的疗法，这些优势足以支撑价格调整，以应对不断上涨的供应成本。最终结果是，供应链的韧性、商业性灵活性以及清晰传达价值提案的能力变得更加重要，这些价值主张能够吸收关税主导的成本波动带来的营运影响，同时又不损害患者的就医机会或临床医生的信心。

多维度细分揭示患者特征、治疗方式和分布动态，从而为有针对性的临床和商业策略提供资讯。

详细的市场细分能清楚展现临床偏好、病患行为和分销动态，进而引导产品开发和推广策略。针对不同类型的药物，治疗方法方案涵盖联合治疗、雷射疗法、口服疗法和局部治疗方法等，每种方案都具有独特的疗效、安全性和依从性特征，这些都会影响临床医生的选择和患者的接受度。治疗方法的选择通常与疾病严重程度、合併症负担以及对快速治疗与持续治疗的偏好密切相关。

考虑到活性成分的差异，诸如阿莫罗芬、环吡咯烷酮、依芬那唑、Fluconazole、伊曲Itraconazole、他伐硼罗和Terbinafine化合物在作用机制、药物动力学和安全性方面表现出许多差异。这些差异决定了附加檔、禁忌症和监测要求，并为药物在临床上与竞争疗法进行定位提供了基础。剂型也至关重要。乳膏、凝胶、指甲油、溶液和胶囊等剂型会影响患者的用药体验，影响患者的依从性，并带来独特的生产和监管方面的考量。

我们的分销管道分析揭示了医院、线上和零售药房管道在决定患者获取药物、获得咨询机会以及销售点动态方面所发挥的作用。治疗场所的细分——居家医疗、住院和门诊诊所——进一步指导了治疗的提供和支持方式，从而影响随访、依从性干预和报销。年龄层（18-65岁、65岁以上和18岁以上）与性别组（女性和男性）相互交织，共同塑造了流行病学趋势，并解决了特定年龄或性别的安全问题。最后，疾病严重程度分类（轻度至中度、復发性和重度）是治疗强度和方案选择的关键驱动因素。整合这些细分层级，使相关人员能够识别目标患者群体，客製化通讯，并优先考虑能够引起製剂研发者和支付方共鸣的临床证据。

评估美洲、欧洲、中东和非洲以及亚太地区的监管多样性、医疗保健融资和通路成熟度如何影响医疗保健的采纳和准入动态。

区域动态对塑造临床实践模式、监管通路和分销基础设施至关重要，进而影响产品的普及。在美洲，成熟的临床网络、广泛的门诊病人服务以及活跃的药房管道，为创新局部用药和全身用药在可靠的安全性和疗效比较证据支持下快速获得临床应用创造了有利环境。日益关注价值和真实世界结果的报销结构和支付方审查，正在影响製剂选择和合约签订方式。

欧洲、中东和非洲地区法律规范和医疗保健资金筹措模式的差异，意味着不同地区的市场准入和推广路径存在显着差异。集中式监管管道与区域性报销谈判并存，使得制定量身定制的上市策略和区域证据包装成为必要。该地区的经销模式也各不相同，有的市场以医院为中心进行采购，有的市场则拥有蓬勃发展的零售和线上药局生态系统，这些都会影响通路的优先排序。

亚太地区拥有庞大的患者群体、不断发展的临床指南以及快速现代化的医疗基础设施。在地化生产能力、某些市场的监管便利管道以及远端保健的日益普及，都会影响治疗方法的评估和应用。在不同地区，人们对皮肤病的文化认知、获得专科医生服务的途径以及药房管道的成熟度，都会影响患者的参与度、诊断的及时性以及长期治疗方案。了解这些区域差异对于协调临床开发、监管申报和商业推广至关重要。

成熟企业和新兴参与企业在临床差异化、製剂领先地位、策略联盟和供应链韧性方面的竞争定位

在甲癣治疗领域，主要企业企业与新兴企业企业之间的动态主要围绕着临床差异化、製剂创新以及在真实世界环境中验证疗效的能力。成熟的药物研发企业凭藉丰富的临床试验经验、广泛的监管知识以及与关键意见领袖和支付方建立的良好关係，保持着竞争优势。同时，规模较小的专业公司和生技公司正透过针对性地研究製剂科学和开发新型作用机制，开启新的市场定位。

策略活动包括重点研发投入，用于开发渗透增强剂和组合方案；与辅助性治疗器械製造商开展合作；以及建立联盟，以促进患者获得专科药房和数位依从性工具。许可协议和区域分销伙伴关係是扩大地域覆盖范围并最大限度减少直接基础设施投资的常用途径。此外，各公司还优先考虑产生患者报告结局和卫生经济学证据，以支持报销谈判并在竞争激烈的治疗层级中脱颖而出。

营运准备，包括生产规模化能力、品管和供应链韧性，仍然是一项关键的竞争优势，尤其是在企业面临关税和采购方面的挑战时。那些将临床差异化与强大的商业化模式和快速分销策略相结合的企业，将赢得临床医生的信任和支付方的认可，并能随着证据和监管环境的变化灵活调整自身定位。

为製造商和相关人员提供切实可行的策略性倡议，以协调证据产生、配方改进和供应链韧性，从而实现可持续的竞争优势。

产业领导者应优先考虑将临床证据产生、製剂创新和供应链应急计画结合的方法。儘早投资于头对头研究和真实世界研究，以了解疗效的持久性、老年患者的安全性以及患者报告的结局，将有助于增强与支付方谈判和临床医生沟通时的价值提案。同时，优化製剂以缩短疗程并提高药物对指甲的渗透性，可以显着提高患者的依从性和满意度，从而建立一个引人注目的商业性故事。

在营运方面，多元化筹资策略、探索近岸生产方案以及与供应商协商关税减免条款，将有助于降低贸易波动风险，并保障供应稳定。销售团队还需要製定针对不同管道的策略，充分考虑医院、线上和零售药房运营的细微差别，同时确保将患者援助计划和数位依从性工具整合到产品上市计划中。

最后，企业领导者应寻求与医疗器材创新者、数位医疗服务提供者和区域经销商建立选择性伙伴关係，以加速产品在重点市场的进入。这些措施的结合——包括以实证医学为导向的临床项目、差异化配方、灵活的采购管道和策略联盟——可以帮助企业获得临床信誉，应对成本压力，并提供在竞争激烈的治疗领域脱颖而出的以患者为中心的解决方案。

严谨的混合方法研究设计，结合了相关人员访谈、系统文献综述和三角验证，在明确的约束条件下，提供了可操作的临床和商业性见解。

研究途径结合了对皮肤科临床医生、药剂师、供应链管理人员和支付方代表的系统性一手调查，以及对监管申报文件、临床试验註册资讯和同行评审文献的广泛二次分析。一手调查优先采用半结构式访谈，以捕捉有关治疗决策驱动因素、未满足的临床需求和运营挑战的细緻观点，从而能够与已发表的临床证据和政策文件进行定性三角验证。

二次研究包括对已发表的临床试验、安全性报告和製剂研究进行系统性回顾，以检验作用机制和比较耐受性。数据综合着重于证据品质、方法透明度和与临床实践的相关性。采用三角测量法来协调相关人员之间的分歧，并确定共识领域和需要进一步研究的证据缺口。

品质保证措施包括对资料提取进行独立审查、采用标准化访谈通讯协定以减少偏倚，以及记录局限性，例如临床实践中的区域异质性和长期结局报告的差异。调查方法旨在突出可操作的见解，同时识别需要额外收集原始资料或进行纵向观察性研究以提高某些临床和经济结论可靠性的领域。

临床创新、供应链韧性与实证商业化对甲癣治疗持续进展的策略意义摘要

总之，甲癣是一个临床需求极高的领域，活性成分、製剂技术和综合治疗方法的进步正在重塑治疗选择。为了取得成功，相关人员必须应对复杂的临床疗效、老年人和併发症族群的安全性考量、不断变化的销售管道以及区域监管差异等诸多挑战。策略性地强调能够证明疗效持久、以患者为中心的便利性和明确的经济价值的证据，对于确保临床医生采纳和支付方支持至关重要。

随着地缘政治和贸易因素的不断演变，营运韧性，尤其是在供应链采购和关税规避方面，将影响产品的可及性和商业性稳健性。那些将临床差异化与切实可行的商业化计划、有针对性的区域策略以及有助于提升市场准入的伙伴关係关係相结合的公司，将更有利于满足未被满足的医疗需求，并建立持久的治疗产品线。持续投资于真实世界证据和患者参与，对于将创新转化为实际改善患者照护至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 雷射治疗甲癣的普及率不断提高，疗效更佳，復发率更低。
  • 越来越多地使用添加了多靶点奈米颗粒载体的局部抗真菌指甲油，以增强其渗透性和疗效。
  • 为了解决患者依从性问题，人们对安全性更高、疗程更短的口服抗真菌药物越来越感兴趣。
  • 远距皮肤病学平台整合实现了甲癣的远距离诊断和治疗，扩大了患者获得专科医生服务的途径。
  • 基于真菌病原体谱分析，开发基因表现以预测甲癣治疗反应并实现个人化治疗

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

灰指甲治疗市场

  • 联合治疗
  • 雷射治疗
  • 口服疗法
  • 局部治疗

灰指甲治疗市场

  • 阿莫罗芬
  • 环吡罗
  • 依芬那康唑
  • Fluconazole
  • Itraconazole
  • 塔瓦博罗勒
  • Terbinafine

第十章 以剂型分類的灰指甲治疗市场

  • 奶油
  • 凝胶
  • 指甲油
  • 解决方案
  • 片剂 胶囊

灰指甲治疗市场

  • 医院药房
  • 网路药房
  • 零售药房

灰指甲治疗市场

  • 居家医疗
  • 住院病人
  • 门诊治疗

灰指甲治疗市场

  • 18至65岁
  • 65岁或以上
  • 未满18岁

第十四章灰指甲治疗市场：性别

  • 女士
  • 男性

灰指甲治疗市场：依疾病严重程度划分

  • 轻度至中度
  • 復发
  • 严重

灰指甲治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

灰指甲治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

灰指甲治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • Sanofi SA
    • Galderma SA
    • Johnson & Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • LEO Pharma A/S
Product Code: MRR-FD3F12D54166

The Onychomycosis Treatment Market is projected to grow by USD 4.30 billion at a CAGR of 9.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.09 billion
Estimated Year [2025] USD 2.29 billion
Forecast Year [2032] USD 4.30 billion
CAGR (%) 9.40%

Framing the modern clinical and commercial landscape of onychomycosis to illuminate unmet needs, stakeholder dynamics, and evolving treatment pathways

Onychomycosis presents a persistent clinical and commercial challenge driven by aging populations, increasing comorbidity prevalence, and evolving patient expectations for tolerability and convenience. Clinicians face diagnostic complexity due to atypical presentations and mixed etiologies, while patients often delay seeking care because of perceived cosmetic concerns and previous treatment failures, creating a landscape where unmet needs remain pronounced.

Recent advances in therapeutic modalities, including more targeted topical antifungals, innovations in oral agents, and adjunctive technologies like laser interventions, have diversified the care pathway and expanded options for different patient profiles. Nevertheless, gaps persist in adherence, long-term relapse prevention, and real-world effectiveness data. Payers and providers are converging on value-driven decision criteria, emphasizing safety profiles, treatment duration, and demonstrable improvements in patient-reported outcomes.

This introduction synthesizes the clinical context, stakeholder dynamics, and the shifting treatment paradigm while setting the stage for deeper exploration of regulatory, economic, and commercial forces that shape product development, market access strategies, and competitive positioning in onychomycosis care.

How therapeutic innovation, formulation advances, and care delivery evolution are redefining treatment choice, adherence, and commercialization in onychomycosis care

The onychomycosis landscape is undergoing transformative shifts as therapeutic innovation intersects with changing patient expectations and delivery models. Treatment approaches are moving beyond single-modality prescriptions toward integrated regimens that combine topical agents, oral therapies, device-based interventions, and supportive measures to improve efficacy and adherence. This multidimensional strategy reframes how clinicians select treatments for mild versus severe disease and how manufacturers position product benefits in clinical messaging.

Simultaneously, investment in formulation science has elevated the role of penetration enhancers, novel vehicle systems, and application convenience, which together address long-standing barriers such as slow nail penetration and prolonged treatment durations. Emerging active ingredients and combination strategies are being tested to reduce relapse rates and improve cure durability, while safety and drug-drug interaction profiles remain central to adoption in populations with polypharmacy, particularly older adults.

On the delivery front, digital channels and telehealth services are reshaping patient access and follow-up, enabling earlier intervention and improved adherence monitoring. Pharmacy models are adapting to this shift, with online pharmacies and home care pathways gaining traction alongside traditional hospital and retail channels. These transformative trends create both opportunities for differentiated clinical value and challenges for market entry, necessitating integrated commercialization plans that account for regulatory nuance, payer expectations, and patient-centric positioning.

Assessing the supply chain, sourcing, and procurement consequences of United States tariff measures through 2025 that are reshaping cost structures and commercialization choices

The introduction of new tariff measures in the United States through 2025 has created a ripple effect across supply chains, procurement strategies, and pricing dynamics for dermatology and antifungal products. Manufacturers that source active pharmaceutical ingredients, excipients, or finished goods internationally are reassessing sourcing footprints and contractual terms to mitigate import duties and customs-related timeline risks. These adjustments often translate into supply planning changes that can affect product availability and inventory buffers at distribution points.

Short-term responses have included shifting component sourcing to domestic or low-tariff jurisdictions, renegotiating supplier agreements to include tariff-sharing clauses, and selectively increasing onshore inventory for critical SKUs. Over time, firms are evaluating nearshore manufacturing and localized formulation facilities as structural responses to tariff-driven cost pressures. These strategic investments reduce exposure to trade volatility but require capital allocation decisions that influence product launch timetables and margin structures.

Payers and procurement teams are also reacting by tightening contracting terms, emphasizing value-based arrangements, and scrutinizing total cost of therapy. Clinical leaders and purchasing departments may favor therapeutics with differentiated safety or adherence advantages that justify adjusted pricing in light of increased supply costs. The net effect is a heightened premium on supply chain resilience, commercial flexibility, and the capacity to communicate clear value propositions that absorb the operational impacts of tariff-driven cost changes without undermining access or clinician trust.

Illuminating patient profiles, therapeutic formats, and distribution dynamics through multi-dimensional segmentation to inform targeted clinical and commercial strategies

Detailed segmentation reveals the contours of clinical preference, patient behavior, and distribution dynamics that inform product development and go-to-market strategies. Across drug type, the therapeutic mix ranges from combination therapy and laser therapy to oral therapy and topical therapy, with each modality carrying distinct efficacy, safety, and adherence profiles that influence clinician selection and patient acceptance. Treatment choice often correlates with disease severity, comorbidity burden, and the desire for rapid versus sustained outcomes.

Considering active ingredient differentiation, compounds such as amorolfine, ciclopirox, efinaconazole, fluconazole, itraconazole, tavaborole, and terbinafine exhibit varied mechanisms of action, pharmacokinetics, and safety considerations. These differences dictate labeling, contraindications, and monitoring needs, and they provide the basis for clinical positioning against competing therapies. Formulation matters as well: cream, gel, nail lacquer, solution, and tablet capsule formats change the patient experience, affect adherence, and present unique manufacturing and regulatory considerations.

Distribution channel analysis highlights the role of hospital pharmacy, online pharmacy, and retail pharmacy pathways in determining access, counseling opportunities, and point-of-sale dynamics. Treatment setting segmentation across home care, hospital inpatient, and outpatient clinic environments further guides how therapies are administered and supported, with implications for follow-up, adherence interventions, and reimbursement. Age group distinctions-18 to 65 years, above 65 years, and below 18 years-intersect with gender segments of female and male patients to shape epidemiologic trends and address age- or gender-specific safety concerns. Finally, disease severity categories of mild to moderate, recurrent, and severe act as primary drivers of therapeutic intensity and regimen selection. Synthesizing these segmentation layers allows stakeholders to identify target patient cohorts, tailor messaging, and prioritize clinical evidence generation that resonates with prescribers and payers alike.

Evaluating how regional regulatory diversity, healthcare financing, and channel maturity across the Americas, EMEA, and Asia-Pacific shape adoption and access dynamics

Regional dynamics are pivotal in shaping clinical practice patterns, regulatory pathways, and distribution infrastructures that affect product adoption. In the Americas, established clinical networks, broad outpatient access, and active pharmacy channels create an environment where both innovative topical formulations and systemic therapies can achieve rapid clinical uptake when supported by robust safety and comparative-effectiveness evidence. Reimbursement mechanisms and payer scrutiny tend to emphasize value and real-world outcomes, influencing formulary decisions and contracting approaches.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous healthcare financing models mean that market entry and adoption trajectories vary significantly across jurisdictions. Centralized regulatory pathways coexist with localized reimbursement negotiations, requiring tailored launch strategies and region-specific evidence packages. Distribution models in this region range from hospital-centric procurement in some markets to thriving retail and online pharmacy ecosystems in others, affecting channel prioritization.

The Asia-Pacific region is characterized by a mix of high-volume patient populations, evolving clinical guidelines, and rapidly modernizing healthcare infrastructures. Local manufacturing capabilities, regulatory acceleration pathways in select markets, and growing telehealth penetration influence how therapies are evaluated and adopted. Across regions, cultural perceptions of dermatologic conditions, access to specialist care, and the maturity of pharmacy channels collectively determine patient engagement, diagnostic timeliness, and long-term management approaches. Understanding these regional nuances is essential for calibrating clinical development, regulatory submissions, and commercial deployment.

Competitive positioning driven by clinical differentiation, formulation leadership, strategic alliances, and supply chain resilience among established and emerging players

Competitive dynamics among leading and emerging companies in onychomycosis are centered on clinical differentiation, formulation innovation, and the ability to demonstrate durable outcomes in real-world settings. Established pharmaceutical developers maintain advantages through broad clinical trial experience, extensive regulatory knowledge, and existing relationships with key opinion leaders and payer bodies. At the same time, smaller specialty firms and biotech entrants are leveraging targeted approaches to formulation science and novel mechanisms of action to carve niche positions.

Strategic activity includes focused R&D investment in penetration enhancers and combination regimens, alliances with device manufacturers for adjunctive therapies, and partnerships that accelerate access to specialty pharmacy and digital adherence tools. Licensing agreements and regional distribution partnerships are common maneuvers to extend geographic reach while minimizing direct infrastructure investment. Additionally, companies are prioritizing the generation of patient-reported outcomes and health-economic evidence to support reimbursement discussions and to differentiate in crowded therapy classes.

Operational readiness-manufacturing scalability, quality control, and supply chain resilience-remains a critical competitive lever, especially as firms navigate tariff and procurement headwinds. Companies that integrate clinical differentiation with robust commercialization models and responsive distribution strategies are positioned to secure clinician trust and payer support, while maintaining flexibility to pivot as evidence or regulatory landscapes evolve.

Practical strategic initiatives for manufacturers and stakeholders to align evidence generation, formulation advances, and supply chain resilience for sustained competitive advantage

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation, formulation innovation, and supply chain contingency planning. Early investments in head-to-head and real-world studies that capture durability of response, safety in older adults, and patient-reported outcomes will strengthen value propositions during payer negotiations and clinician engagement. Concurrently, optimizing formulations to reduce treatment duration and enhance nail penetration can materially improve adherence and patient satisfaction, creating a compelling commercial narrative.

On the operational front, diversifying sourcing strategies, exploring nearshore manufacturing options, and implementing tariff-mitigation clauses with suppliers will reduce exposure to trade volatility and support stable supply. Commercial teams must also cultivate channel-specific strategies that reflect the nuances of hospital pharmacy, online pharmacy, and retail pharmacy operations, while ensuring that patient support programs and digital adherence tools are integrated into launch plans.

Finally, leaders should pursue selective partnerships with device innovators, digital health providers, and regional distributors to accelerate access in priority markets. These combined actions-evidence-focused clinical programs, formulation differentiation, resilient sourcing, and strategic alliances-will enable organizations to capture clinical credibility, manage cost pressures, and deliver patient-centered solutions that stand out in a competitive therapeutic area.

A rigorous mixed-methods research design combining stakeholder interviews, systematic literature review, and triangulation to provide actionable clinical and commercial insights with transparent limitations

The research approach combined structured primary engagement with dermatology clinicians, pharmacists, supply chain managers, and payer representatives alongside extensive secondary analysis of regulatory filings, clinical trial registries, and peer-reviewed literature. Primary research prioritized semi-structured interviews to capture nuanced perspectives on treatment decision drivers, unmet clinical needs, and operational challenges, enabling qualitative triangulation with publicly available clinical evidence and policy documents.

Secondary research involved systematic review of published clinical trials, safety reports, and formulation studies to validate mechanistic claims and comparative tolerability profiles. Data synthesis emphasized evidence quality, methodological transparency, and relevance to real-world clinical practice. Triangulation techniques were applied to reconcile differing stakeholder viewpoints and to identify consensus areas as well as evidence gaps that warrant further study.

Quality assurance measures included independent review of data extraction, standardized interview protocols to reduce bias, and documentation of limitations such as regional heterogeneity in clinical practice and variability in long-term outcome reporting. The methodology was designed to foreground actionable insights while acknowledging areas where additional primary data collection or longer-term observational studies would strengthen confidence in specific clinical or economic conclusions.

Summarizing the strategic implications of clinical innovation, supply chain resilience, and evidence-driven commercialization for sustained progress in onychomycosis care

In conclusion, onychomycosis remains an area of high clinical need where advances in active ingredients, formulation technologies, and integrated treatment approaches are reshaping therapeutic choices. Stakeholders must navigate a complex interplay of clinical efficacy, safety considerations in older and comorbid populations, distribution channel evolution, and regional regulatory diversity to succeed. Strategic emphasis on evidence that demonstrates durable outcomes, patient-centered convenience, and clear economic value will be decisive in securing clinician adoption and payer support.

Operational resilience-particularly in supply chain sourcing and tariff mitigation-will influence product availability and commercial robustness as geopolitical and trade factors continue to evolve. Companies that combine clinical differentiation with pragmatic commercialization plans, targeted regional strategies, and partnerships to enhance access will be best positioned to address unmet needs and build lasting therapeutic franchises. Continued investment in real-world evidence and patient engagement will remain central to translating innovation into meaningful improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of laser-based onychomycosis treatments with improved efficacy and reduced recurrence
  • 5.2. Rising utilization of topical antifungal nail lacquers formulated with multitarget nanoparticle carriers to enhance penetration and efficacy
  • 5.3. Growing interest in oral antifungal agents with improved safety profiles and shorter treatment duration to address patient compliance
  • 5.4. Integration of teledermatology platforms for remote diagnosis and management of onychomycosis to expand patient access to specialists
  • 5.5. Development of gene expression biomarkers to predict treatment response and personalize onychomycosis therapy based on fungal pathogen profiling

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Onychomycosis Treatment Market, by Drug Type

  • 8.1. Combination Therapy
  • 8.2. Laser Therapy
  • 8.3. Oral Therapy
  • 8.4. Topical Therapy

9. Onychomycosis Treatment Market, by Active Ingredient

  • 9.1. Amorolfine
  • 9.2. Ciclopirox
  • 9.3. Efinaconazole
  • 9.4. Fluconazole
  • 9.5. Itraconazole
  • 9.6. Tavaborole
  • 9.7. Terbinafine

10. Onychomycosis Treatment Market, by Formulation

  • 10.1. Cream
  • 10.2. Gel
  • 10.3. Nail Lacquer
  • 10.4. Solution
  • 10.5. Tablet Capsule

11. Onychomycosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Onychomycosis Treatment Market, by Treatment Setting

  • 12.1. Home Care
  • 12.2. Hospital Inpatient
  • 12.3. Outpatient Clinic

13. Onychomycosis Treatment Market, by Age Group

  • 13.1. 18 To 65 Years
  • 13.2. Above 65 Years
  • 13.3. Below 18 Years

14. Onychomycosis Treatment Market, by Gender

  • 14.1. Female
  • 14.2. Male

15. Onychomycosis Treatment Market, by Disease Severity

  • 15.1. Mild To Moderate
  • 15.2. Recurrent
  • 15.3. Severe

16. Onychomycosis Treatment Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Onychomycosis Treatment Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Onychomycosis Treatment Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Novartis AG
    • 19.3.2. Pfizer Inc.
    • 19.3.3. Bausch Health Companies Inc.
    • 19.3.4. Bayer AG
    • 19.3.5. Sanofi S.A.
    • 19.3.6. Galderma S.A.
    • 19.3.7. Johnson & Johnson Services, Inc.
    • 19.3.8. Teva Pharmaceutical Industries Ltd.
    • 19.3.9. Viatris Inc.
    • 19.3.10. LEO Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONYCHOMYCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 201